Realizing that a number of malignant tumors rely on iNOS/NO signaling for a survival, proliferative, and metastatic advantage, many investigators have advocated pharmacologic use of iNOS inhibitors to curb tumor progression [13,14,15,33]. The gene discussed is NOS2; the disease is cancer.